Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and linked to poor prognosis, highlighting the need for new therapies. The trial aims to explore whether this combination can improve treatment outcomes by targeting cancer cells through different mechanisms. Genmab will lead the study, with Incyte co-funding and supplying INCB161734, reflecting a strategic collaboration to address an unmet medical need.

Incyte Corporation holds a market cap of $23.46 billion and an enterprise value of $18.96 billion as of Oct 24, 2026, 18:11 WIB. On Pluang, Incyte's stock price is USD 115.71, down 1.04% for the day, with a trading volume of 1,476,818 shares and a typical hold time of 33 days. This trading activity occurs amid the company's announcement of a clinical trial collaboration targeting metastatic colorectal cancer, highlighting ongoing investor interest in its health sector innovations.